Powering the Tumour: How a Mitochondrial Protein Drives Lung Cancer

Lung cancer cells have a voracious appetite for energy, and new research has identified a specific protein that helps keep their engines running. The study focuses on mitochondrial ribosomal protein S12 (MRPS12), which is significantly overexpressed in patients with non-small cell lung cancer (NSCLC) and associated with unfavourable clinical results.

When scientists used genetic tools like CRISPR-Cas9 to silence MRPS12, the consequences for the cancer cells were severe. Their mitochondria—the cellular power plants—began to fail, leading to a sharp drop in ATP (energy) levels and a damaging spike in reactive oxygen species. Consequently, the cells lost their ability to proliferate or migrate and often underwent apoptosis, or self-destruction.

These findings were confirmed in vivo, where silencing MRPS12 markedly inhibited tumour growth in mice. The treated tumours showed signs of oxidative injury and reduced activation of the Akt-mTOR signalling pathway, a key route for cancer progression. This suggests that targeting MRPS12 could be a promising strategy to cut the power to malignant cells.